Synairgen plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYGGF research report →
About the company
Synairgen plc is a biopharmaceutical company focused on the discovery and advancement of therapeutic drugs for various respiratory conditions. Their product pipeline features SNG001, an inhaled interferon beta under development for the treatment of COVID-19. They are also conducting Phase II clinical trials for an inhaled formulation of interferon beta (IFN-ß), targeting both asthma exacerbated by the common cold and flu, and the treatment or prevention of chronic obstructive pulmonary disease (COPD).
- CEO
- Joseph Tregonning Colliver
- IPO
- 2020
- Employees
- 36
- HQ
- Southampton, GB
Price Chart
- Market Cap
- $110.27K
- P/E
- -0.23
- P/S
- 0.00
- P/B
- 0.15
- EV/EBITDA
- -0.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -51.06%
- ROIC
- -70.80%
- Revenue
- $0 · 0.00%
- Net Income
- $-6,811,000 · 18.99%
- EPS
- $-0.03 · 19.14%
- Op Income
- $-8,324,000
- FCF YoY
- 4.00%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 6.56
- Avg Volume
- 6.67K
Get TickerSpark's AI analysis on SYGGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SYGGF coverage
Recent articles, reports, and earnings notes.
No research on SYGGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SYGGF report →Similar companies
Peers in the same neighborhood.